Full Proxy Statement Filed for Yarrow Bioscience Reverse Merger, Detailing Shareholder Vote on Dilution, Cash Dividend, and Reverse Split
VYNE has more than doubled off its 52-week low of $0.281.
Summary
VYNE Therapeutics filed the full proxy statement for its reverse merger with Yarrow Bioscience, detailing the significant dilution for existing shareholders, a cash dividend, and a large capital raise for the combined entity, all subject to shareholder approval.
Key Events · M&A and Partnerships · VYNE
-
Reverse Merger Details Confirmed
VYNE Therapeutics is proceeding with a reverse merger with Yarrow Bioscience, Inc., with VYNE to be renamed 'Yarrow Bioscience, Inc.' and trade under the symbol 'YARW' on Nasdaq.
-
Significant Shareholder Dilution
Existing VYNE securityholders are expected to own approximately 3.0% of the outstanding shares of the Combined Company on a fully-diluted basis post-merger.
-
Substantial Capital Raise for Yarrow
The transaction includes a $200 million aggregate pre-closing financing for Yarrow, comprising a $100 million private placement already closed and an additional $100 million pre-closing financing.
-
Special Cash Dividend for VYNE Shareholders
Prior to the merger, VYNE expects to declare a special cash dividend of approximately $14.5 million to $16.5 million to its existing shareholders.
Analysis · VYNE · Life Sciences
This S-4 filing provides the comprehensive proxy statement and prospectus for the proposed reverse merger with Yarrow Bioscience. It details the significant dilution for existing VYNE shareholders, who are expected to own only 3.0% of the combined company, alongside a substantial $200 million pre-closing financing for Yarrow. The filing also outlines a special cash dividend of $14.5 million to $16.5 million for current VYNE shareholders and the necessity of a reverse stock split (1-for-10 to 1-for-70) to maintain Nasdaq listing. This document is critical for shareholders to make informed decisions on the transformative transaction, which represents a strategic pivot for VYNE from its struggling legacy business.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.1% of the 367 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VYNE was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.5M. The 52-week trading range was $0.28 to $1.96. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.